vormatrogine
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Epilepsy, Tonic-Clonic
Conditions
Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Trial Timeline
Oct 27, 2025 → Dec 31, 2028
NCT ID
NCT07287163About vormatrogine
vormatrogine is a phase 3 stage product being developed by Praxis Precision Medicines for Epilepsy, Tonic-Clonic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07287163. Target conditions include Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07287163 | Phase 3 | Recruiting |
Competing Products
20 competing products in Epilepsy, Tonic-Clonic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| perampanel | Eisai | Phase 2 | 52 |
| Lacosamide | UCB | Phase 3 | 74 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Zonegran | Eisai | Approved | 85 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| perampanel | Eisai | Approved | 85 |
| E2007 + Placebo | Eisai | Phase 2 | 52 |
| Placebo + Rufinamide | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| Perampanel Oral Tablet | Eisai | Approved | 85 |
| perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Carbamazepine | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Phase 2 | 52 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide low dose group + zonisamide high dose group | Eisai | Approved | 85 |
| E2007 + E2007 + Placebo | Eisai | Phase 2 | 52 |